06:32 AM EST, 11/05/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Wednesday that it has accepted the US Inflation Reduction Act's Maximum Fair Price, or MFP, for its semaglutide-based Ozempic, Rybelsus, and Wegovy products, in Medicare Part D.

The company said the prices will be effective as of January 2027.

Novo Nordisk ( NVO ) did not disclose specific pricing details but said it would have had a "negative low single-digit impact on global sales growth" for the full year 2025 had it been implemented on Jan. 1, 2025.